Browse by Audience
MEMBER

Update Your Profile
Member Spotlights
Refer a Member: IASP Champions
Join a Special Interest Group (SIG)
Find a Chapter
Join Now

RESEARCHER

PAIN
PAIN Reports
Pain Research Forum
Papers of the Week
Webinars and Podcasts
Events

HEALTH CARE PROVIDER

Online Learning - PERC
Webinars & Podcasts
Curricula
Graduate Opportunities
Events

PATIENT & CAREGIVER

RELIEF News
Resources for Living with Pain
Global Alliance of Partners in Pain Advocacy (GAPPA)
Events

PARTNER

Support IASP
Sponsor an Event
Become a Partner

gy2022-1-3
I am a
IASP Logo
Home I AM A Search Login

Papers of the Week

Home / Publications / Pain Research Forum / Papers of the Week / Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.

< BACK TO ARCHIVE


Papers: 22 Feb 2020 - 28 Feb 2020


Human Studies, Pharmacology/Drug Development

PAIN TYPE:
Migraine/Headache


2020 Feb 24


J Headache Pain


http://www.ncbi.nlm.nih.gov/pubmed/32093628?dopt=Abstract


21


1

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.

Authors

Trajectory of migraine-related disability following long-term treatment with lasmiditan: results of the GLADIATOR study.
Lipton RB, Lombard L, Ruff DD, Krege JH, Loo L S, Buchanan A, Melby TE, Buse DC
J Headache Pain. 2020 Feb 24; 21(1):20.
PMID: 32093628.

Abstract

Migraine is recognized as the second leading cause of disability globally. Lasmiditan is a novel, selective serotonin 5-HT receptor agonist developed for acute treatment of migraine. Here we analyzed effects of lasmiditan on migraine disability assessed with the Migraine Disability Assessment (MIDAS) scale for interim data from a long-term safety study.
Read This Paper